|
|
Selzentry (Maraviroc, Celsentri)
| Brand Name: |
Selzentry |
| Generic Name: |
Maraviroc, MVC |
| Adult Single Dose*: |
One 300 mg tablet twice daily |
| Food & Liquid Restrictions: |
None. |
| Drug Class: |
Entry Inhibitor |
|
|
|
READ FIRST:
- Selzentry (Maraviroc, MVC, Formerly UK-427,857) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- An Overview of Selzentry (Maraviroc, Celsentri) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- The Basics on Maraviroc: An Interview With Joel Gallant, M.D., M.P.H. (August 6, 2007)
From The Body
The Basics
News & Research
- IPM Reaches Landmark Agreement With Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide (January 30, 2008)
From International Partnership for Microbicides
- ICAAC: Maraviroc Failures Associated With Shifts From R5-Tropic to Mixed or X4-Tropic HIV (September 20, 2007)
From aidsmap.com
- IAS: Maraviroc Produces Best Results When Combined With Another Active Drug (August 14, 2007)
From aidsmap.com
- Clinical Data Show Pfizer's Antiretroviral Maraviroc Reduces HIV Viral Loads Among Treatment-Naive People, Company Says (July 26, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Maraviroc Underperforms Efavirenz in Treatment-Naive Study (July 25, 2007)
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- European Advisory Panel Recommends Approval of Pfizer's Antiretroviral Maraviroc, Company Says (July 23, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Held Up in U.S., First CCR5 Inhibitor Nears Approval in Europe (July 20, 2007)
From aidsmap.com
- Pfizer Advises Maraviroc Dose Increase if Combined With Etravirine (July 20, 2007)
From aidsmap.com
- Maraviroc Approval Is Delayed in United States (June 21, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Treatment Action Group Supports Maraviroc Approval (May 1, 2007)
From Treatment Action Group
- FDA Panel Recommends Agency Approve Pfizer's Antiretroviral Maraviroc (April 25, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- CROI: Maraviroc Shows Potent Effect in Highly Treatment-Experienced (February 28, 2007)
From aidsmap.com
- Maraviroc + OBT Potent in Treatment-Experienced HIV-Infected Patients: An Interview With Roy Gulick, M.D. (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Phase 3 Results of Two Key Trials of Maraviroc, the First-in-Class CCR5 Antagonist (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- FDA Panel to Consider Pfizer's Second-Line HIV Drug (February 9, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- United States: Pfizer to Expand Access to HIV Drug (December 5, 2006)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- HIV Antiretroviral Agents in Development: Entry Inhibitors (March 30, 2006)
From The Body
- Once-Daily Arm in Maraviroc Treatment-Naive Study Terminated (January 30, 2006)
From aidsmap.com
- Case Study of a Patient With Serious Hepatotoxicity in Maraviroc 2b/3 Trial Reported at Targeting HIV Entry -- 1st International Workshop (December 3, 2005)
To read PDF, click here
From Pfizer, Inc.
- The CCR5 Antagonist UK-427,857 (Maraviroc) Shows Strong Activity in Phase 1/2a Monotherapy Studies (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Entry Inhibitors in Development (July 2004)
Brief updates on PRO 542, SCH-D, UK-427,857 and GW-873140.
To read PDF, click here
In Project Inform Perspective, from Project Inform
|
|
